The patient who does not know they have rosacea
Some of the most instructive patients in my cornea clinic arrive labeled as "chronic " or "dry eye that nothing helps." Their cheeks may flush with heat or spicy food, or their skin may look almost normal. Only when I turn their eyelids and express the meibomian glands does the pattern declare itself: this is .
Ocular involvement is common in rosacea and can precede the skin findings, which is precisely why it is underdiagnosed. The dermatologist treats the cheeks, the ophthalmologist treats the tears, and the lid margin, where the disease actually lives, belongs to no one. Add that its signs, such as redness, burning, and recurrent styes, look like ordinary blepharitis, and years can pass before the pieces are connected.
What I look for
- Telangiectatic vessels along the eyelid margin, the single most telling clue
- Plugged or pouting meibomian orifices with cloudy, sometimes toothpaste-like secretions
- Recurrent , especially in the same lids
- Evaporative dry eye that seems out of proportion to tear volume
- A history of facial flushing, or triggers such as heat, sun, spicy food, and alcohol
- In more advanced disease, conjunctival hyperemia and corneal neovascularization at the lower limbus
The link to is the engine of the disease: inflamed, obstructed glands produce poor oil, the tear film evaporates, and the ocular surface becomes inflamed in turn, feeding the loop.
Plump oil sacs (acini) surround an open central duct, and oil flows freely out of the orifice into your tear film.
Meibomian glands inside the eyelid make the oil that keeps your tears from evaporating. Drag to rotate — and see how the gland changes as blockage progresses.
What the biology is telling us
This loop has been the focus of my own research for years. Our group showed that patients with ocular rosacea carry measurable oxidative stress, both at the ocular surface and systemically, along with increased Toll-like receptor 4 expression, findings that frame rosacea as a whole-body inflammatory tendency rather than a local lid problem.
This year, work I joined with international colleagues took the story deeper. In our paper "Cross-species transcriptomics identify mineralocorticoid receptor pathway overactivation as a central driver of ocular rosacea," published in Nature Communications in 2026, we showed that overactivation of the mineralocorticoid receptor pathway drives meibomian gland dysfunction and the ocular surface damage of rosacea across species. The study also points to S100A9 as a candidate biomarker and, importantly, shows that blocking the mineralocorticoid receptor is a plausible therapeutic strategy. For a field that has long relied on warm compresses and empirical tetracyclines, having a mechanistic target feels genuinely new.
Pearls I keep returning to
- At every dry eye visit, look at the face before the slit lamp; the skin often gives the answer first.
- Always express the meibomian glands. A clear diagnosis of gland dysfunction changes the whole plan.
- Treat the lid, not only the tear film: lid hygiene and heat for the glands, with anti-inflammatory or in-office therapies added when needed.
- Set expectations early. Rosacea is a chronic condition we control together, not an infection we cure once.
- Work with dermatology. Patients do best when both ends of the disease are managed.
The next time a patient tells me their eyes "burn for no reason," I will keep looking at their eyelids, and now also at their biology.